Considered and approved the financial results for the quarter and half year ended 30th September 2025
KPL · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Kwality Pharmaceuticals reported strong H1 FY26 results with consolidated revenue rising 31% year-on-year to ₹222.5 crore (from ₹170 crore in H1 FY25), driven by robust sales in international markets. EBITDA grew 35% to ₹50 crore, with margins improving to 22.5% from 22.0% in the previous quarter. Net profit surged nearly 55% to ₹26 crore (from ₹16.85 crore). Standalone Q2 FY26 revenue jumped about 26% YoY to ₹113.1 crore, with PAT of ₹14.1 crore (vs ₹8.5 crore). The statutory auditor (Vijay Mehra & Co.) issued an unqualified limited review report with no qualifications. The company generated positive operating cash flow of ₹26.8 crore, and all capex was funded internally. Management guided Q3 FY26 revenue of around ₹140 crore and reiterated its ₹500 crore FY26 revenue target, backed by new product registrations and capex in Biologics, Oncology and Hormone facilities.
Strong double-digit growth across revenue, EBITDA and PAT, combined with margin expansion and clean auditor opinion, signals healthy operational momentum for shareholders. The positive outlook and self-funded expansion support a constructive view on the stock's near-term trajectory.